MGI is pleased to announce the appointment of Decode Science as the distributor for the MGI range of next generation sequencers and related products in Australia and New Zealand regions. This partnership levers the strengths of both organisations to provide strong local support for customers. ABN: 24 615 709 245 Email: sales@decodescience.com.au Contact: Joshua Warburton About Decode Science Decode Science is a privately owned Australian organisation specialising in the Life Science mark...

The bio-nanotechnology innovator Xing Technologies (hereinafter “XING”) is a UQ spin-off enterprise specialising in world-leading disease diagnosis and monitoring technologies, including cancer. Its proprietary nano-technologies are transforming the future practice of medicine and healthcare. BGI, a global genomics giant, is the largest organisation in the world in genomics research and applications. With its strong technological capabilities and expertise in gene sequencing and instrument de...

MGI, a subsidiary corporation of BGI, has obtained the Medical Device Registration Certificate (MDRC) from ChinaFood and Drug Administration (CFDA) for its two next-generation sequencers, MGISEQ-2000 and MGISEQ-200. On June 30, 2014, CFDA approved the registrations of MGI's first two sequencers, which made MGI the first organization to receive the certification from CFDA for next-generation sequencing diagnostic products and medical devices. During this short period of continuous developmental p...

Heading to the 28th ECCMID( European Congress of Clinical Microbiology and Infectious Diseases) in Madrid, Spain, from April 21 - 24, 2018. MGI and Curetis can be found at booth #79, hall 10, during the conference. The Company will also provide an update on its Unyvero A30 RQ Analyzer and its first A30 RQ Application Cartridge, which are in development for expected CE-IVD marking in 2019. The A30 RQ Analyzer for low- to mid-plex testing will complement the current Unyvero A50 Analyzer for high-...